Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study.Therapeutic advances in hematology · 2024
   Article
2. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.Leukemia · 2023
   Article
3. Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.Cancers · 2021
   Article
4. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.Frontiers in immunology · 2021
   Review
5. Bone marrow niche dysregulation in myeloproliferative neoplasms.Haematologica · 2020
   Review
6. The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.Cancers · 2019
   Article
7. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.Haematologica · 2019
   Article
8. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
   Article
9. Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Current hematologic malignancy reports · 2015
   Review
10. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.Mediators of inflammation · 2015
    Review
11. The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Cancers · 2014
    Review
12. Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Mediterranean journal of hematology and infectious diseases · 2014
    Article
13. Preclinical models for drug selection in myeloproliferative neoplasms.Current hematologic malignancy reports · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as